GeoVax Labs, Inc. (GOVX)

Over the past six months, GeoVax Labs, Inc. stock price has experienced a significant decline. Key events impacting the stock price include a reverse stock split, dilutive equity offerings, financial losses and cash runway concerns, and the termination of the BARDA Project NextGen contract. The company executed a 1-for-25 reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement. The company undertook multiple dilutive equity offerings to raise capital, which increased shareholder dilution. GeoVax Labs continued to report significant financial losses, leading to concerns about a critically short cash runway. The termination of the BARDA contract negatively impacted the company's revenue.

As a clinical-stage biotechnology company, the demand seasonality for GeoVax Labs, Inc.'s products and services is primarily driven by disease outbreaks, public health initiatives, regulatory approvals, and the progression of clinical trials, rather than typical seasonal consumer patterns. Historically, July has been the strongest month for GOVX stock, while February tends to be the weakest month.

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing human vaccines and immunotherapies for infectious diseases and solid tumor cancers, operating within the Healthcare sector, specifically in the Biotechnology industry, and utilizing a proprietary Modified Vaccinia Ankara (MVA) virus-like particle (VLP) vaccine platform. Its major product pipeline includes preventive vaccines targeting COVID-19, Mpox and Smallpox, Hemorrhagic Fever Viruses, Malaria, Zika Virus, and Human Immunodeficiency Virus (HIV). Additionally, GeoVax is developing therapeutic vaccines and immunotherapies for HIV, Chronic Hepatitis B infections, and Solid Tumor Cancers.

GeoVax Labs, Inc. primarily operates in the United States, with its corporate headquarters located in Smyrna, Georgia. In the fourth quarter of 2025, the company announced the relocation of its corporate headquarters to 1955 Lake Park Drive in Smyrna, Georgia, and its laboratory operations to Science Square / Portal Innovations in midtown Atlanta to support growth and pipeline advancement.

Direct information specifically detailing "brand reputation" in terms of public perception or media sentiment beyond financial performance is limited. GeoVax Labs has a consensus "Hold" rating from Wall Street analysts. Events that have affected the company's standing include the BARDA NextGen Contract Termination, NASDAQ Compliance Issues, and a strategic partnership with BARDA.

As of March 27, 2026, GeoVax Labs, Inc. has 5 institutional owners and shareholders holding a total of 4,124 shares, with institutional investors owning 6.09% of the stock. Insider ownership is notably high, with insiders owning 81.37% of the company's shares. University Emory is reported as the largest individual GeoVax Labs shareholder. Insider sentiment has been positive, fueled by high-impact open-market purchases from 11 different insiders.